COLÍRIO LEGRAND
144,90 R$
Max. consumer price (CMED)
Analogs of COLÍRIO LEGRAND
Find cheaper analogs and generic equivalents for COLÍRIO LEGRAND.
Substancja czynna: zinc heptaidratado sulfate, nafazoline hydrochloride
Przegląd produktu
About COLÍRIO LEGRAND
COLÍRIO LEGRAND is a medicinal ophthalmic solution formulated to provide relief for ocular discomfort. This product is designed for topical application directly into the eyes to address specific symptoms related to minor irritations. As a sterile solution, it adheres to pharmaceutical standards for safety and efficacy in ocular care. It is intended for use by individuals seeking to manage redness or irritation caused by environmental factors or fatigue. Always ensure the container remains tightly closed when not in use to maintain the sterility of the solution.
Key Benefits & Uses
- Provides temporary relief from minor eye redness.
- Helps soothe discomfort associated with ocular irritation.
- Formulated for convenient topical administration.
Active Ingredient & Action
The therapeutic effect of COLÍRIO LEGRAND is derived from two primary active components: zinc heptaidratado sulfate and nafazoline hydrochloride. Nafazoline hydrochloride acts as a vasoconstrictor, which helps to reduce the appearance of redness by narrowing the blood vessels in the eye. Zinc heptaidratado sulfate serves as an astringent, contributing to the soothing action of the medication upon contact with the ocular surface.
Important Notes
Consult a healthcare professional or ophthalmologist before beginning use of COLÍRIO LEGRAND to ensure it is appropriate for your specific condition. Do not use this product if you have a known hypersensitivity to any of the active ingredients. If you experience persistent pain, changes in vision, or worsening irritation, discontinue use immediately and seek medical advice. Keep this medication out of the reach of children and store it in a cool, dry place away from direct sunlight.
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.